Blog
RSS FeedPosted by Michael Wonder on 10 May 2021
A refreshed evidence standards framework for digital health technologies and an increased focus on digital health for NICE
10 May 2021 - Two exciting developments which will accelerate NICE’s efforts to deliver innovation to the health and care system ...
Posted by Michael Wonder on 07 May 2021
Avelumab not recommended as a maintenance treatment of urothelial cancer after platinum-based chemotherapy
7 May 2021 - NICE has issued draft guidance which does not recommend avelumab for maintenance treatment of locally advanced or ...
Posted by Michael Wonder on 06 May 2021
Preliminary NICE 'no' for Merck's Bavencio
6 May 2021 - NICE has issued a preliminary rejection of NHS funds for use of Merck Serono's Bavencio (avelumab) ...
Posted by Michael Wonder on 04 May 2021
NICE announces more people eligible for nusinersen sodium following review of Managed Access Agreement
4 May 2021 - NICE has today announced that more people with the rare genetic disorder spinal muscular atrophy are to ...
Posted by Michael Wonder on 28 Apr 2021
Do existing real world data sources generate suitable evidence for the HTA of medical devices in Europe? Mapping and critical appraisal
28 April 2021 - Technological and computational advancements offer new tools for the collection and analysis of real world data. ...
Posted by Michael Wonder on 28 Apr 2021
NICE signs up to join the GetReal Institute
28 April 2021 -NICE’s ambition complements the GetReal Institute’s core mission to facilitate the adoption and implementation of real-world evidence ...
Posted by Michael Wonder on 28 Apr 2021
Thousands with high cholesterol set to benefit from new treatment on the NHS
28 April 2021 - Thousands of people with high cholesterol will soon have access to a new treatment option on the ...
Posted by Michael Wonder on 22 Apr 2021
The thorny issue of value alignment: how development-focused health technology assessment can help find win–win situations for patients and health care systems and commercial investors
20 April 2021 - We agree that there is always likely to be some tension between commercial interests and maximising societal ...
Posted by Michael Wonder on 22 Apr 2021
NICE recommends new treatment for rare blood disorder
22 April 2021 - Hundreds of people with a rare blood disorder have access to a new treatment regimen following draft ...
Posted by Michael Wonder on 22 Apr 2021
Delcath Systems announces revised NICE guidance for Chemosat in the United Kingdom
21 April 2021 - Recommends special arrangement designation which increases reimbursement options. ...
Posted by Michael Wonder on 21 Apr 2021
Novartis’ MS therapy Kesimpta wins NICE backing
21 April 2021 - Novartis’ Kesimpta has been recommended by NICE for the treatment of relapsing-remitting multiple sclerosis in adult ...
Posted by Michael Wonder on 21 Apr 2021
Chemotherapy-free treatment option to be offered to patients with England’s most common leukaemia
20 April 2021 - Acalabrutinib, taken as a twice daily tablet, is recommended as an option for adults with untreated ...
Posted by Michael Wonder on 20 Apr 2021
NICE’s five year strategy sets a ‘positive vision for the future’
20 April 2021 - The pharma industry has responded to the NICE new five year strategy, announced yesterday. ...
Posted by Michael Wonder on 20 Apr 2021
NICE draft guidance provides Cancer Drugs Fund first in Europe access to new treatment option for advanced breast cancer
20 April 2021 - NICE has today published draft guidance recommending trastuzumab deruxtecan for use in the Cancer Drugs Fund for ...
Posted by Michael Wonder on 19 Apr 2021
NICE launches ambitious strategy to provide quicker access to new treatments and innovations
19 April 2021 - NICE will transform key elements of its approach to ensure efficiency and speed while maintaining robust, trusted ...